Cetera Investment Advisers Buys 11,221 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Cetera Investment Advisers grew its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 35.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 43,114 shares of the biopharmaceutical company's stock after acquiring an additional 11,221 shares during the period. Cetera Investment Advisers' holdings in Catalyst Pharmaceuticals were worth $900,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth $27,000. Farther Finance Advisors LLC boosted its position in Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after acquiring an additional 1,495 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter worth about $65,000. KBC Group NV raised its position in shares of Catalyst Pharmaceuticals by 48.8% in the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after acquiring an additional 1,542 shares in the last quarter. Finally, Quarry LP acquired a new position in shares of Catalyst Pharmaceuticals in the 4th quarter valued at about $104,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Trading Up 0.2%

NASDAQ CPRX traded up $0.04 during trading hours on Thursday, hitting $24.58. The company's stock had a trading volume of 933,233 shares, compared to its average volume of 1,104,644. The company has a market capitalization of $3.00 billion, a PE ratio of 20.83, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.75 and a 52 week high of $26.16. The company's 50-day simple moving average is $23.59 and its two-hundred day simple moving average is $22.59.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on CPRX shares. Stephens reaffirmed an "overweight" rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Wall Street Zen raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. HC Wainwright reiterated a "buy" rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Finally, Robert W. Baird raised their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, March 3rd. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $32.29.

Insider Activity

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now directly owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This represents a 25.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. The trade was a 39.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 351,879 shares of company stock worth $8,214,815 over the last quarter. Insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.